{
    "organizations": [],
    "uuid": "7526b7ad0a498ee2b3ea117913c20c1e60086ba0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-melinta-therapeutics-partner-menar/brief-melinta-therapeutics-partner-menarini-group-submits-marketing-authorization-application-for-delafloxacin-in-europe-idUSFWN1QQ0MP",
    "ord_in_thread": 0,
    "title": "BRIEF-Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application For Delafloxacin In Europe",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Melinta Therapeutics, Inc.:\n* MELINTA THERAPEUTICS PARTNER, MENARINI GROUP, SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DELAFLOXACIN IN EUROPE\n* MELINTA THERAPEUTICS, INC. - MENARINI GROUP SUBMITTED MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR DELAFLOXACIN Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T20:21:00.000+02:00",
    "crawled": "2018-03-09T14:23:19.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "melinta",
        "therapeutic",
        "melinta",
        "therapeutic",
        "partner",
        "menarini",
        "group",
        "submits",
        "marketing",
        "authorization",
        "application",
        "delafloxacin",
        "europe",
        "melinta",
        "therapeutic",
        "menarini",
        "group",
        "submitted",
        "marketing",
        "authorization",
        "application",
        "european",
        "medicine",
        "agency",
        "delafloxacin",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}